Colgate-Palmolive Company $CL Shares Sold by Saratoga Research & Investment Management

Saratoga Research & Investment Management reduced its position in Colgate-Palmolive Company (NYSE:CL) by 3.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 186,563 shares of the company’s stock after selling 7,532 shares during the quarter. Colgate-Palmolive makes up about 0.8% of Saratoga Research & Investment Management’s holdings, making the stock its 28th largest holding. Saratoga Research & Investment Management’s holdings in Colgate-Palmolive were worth $14,742,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Maseco LLP acquired a new position in Colgate-Palmolive in the 4th quarter valued at $27,000. Copia Wealth Management acquired a new position in Colgate-Palmolive in the 3rd quarter valued at $29,000. Cloud Capital Management LLC acquired a new position in Colgate-Palmolive in the 3rd quarter valued at $30,000. Global Wealth Strategies & Associates increased its stake in Colgate-Palmolive by 300.0% in the 4th quarter. Global Wealth Strategies & Associates now owns 400 shares of the company’s stock valued at $32,000 after buying an additional 300 shares during the period. Finally, Camelot Portfolios LLC acquired a new position in Colgate-Palmolive in the 4th quarter valued at $32,000. 80.41% of the stock is owned by institutional investors and hedge funds.

Colgate-Palmolive Price Performance

Colgate-Palmolive stock opened at $88.20 on Friday. Colgate-Palmolive Company has a 52 week low of $74.54 and a 52 week high of $99.33. The company has a quick ratio of 0.67, a current ratio of 1.02 and a debt-to-equity ratio of 16.33. The firm’s 50-day simple moving average is $86.30 and its 200 day simple moving average is $84.68. The firm has a market capitalization of $70.76 billion, a PE ratio of 34.32, a P/E/G ratio of 4.57 and a beta of 0.31.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings data on Friday, May 1st. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.94 by $0.03. Colgate-Palmolive had a net margin of 10.04% and a return on equity of 386.76%. The business had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.22 billion. During the same period in the previous year, the firm earned $0.91 EPS. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. On average, equities research analysts predict that Colgate-Palmolive Company will post 3.82 EPS for the current fiscal year.

Colgate-Palmolive Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Monday, April 20th were given a $0.53 dividend. The ex-dividend date was Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.4%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. Colgate-Palmolive’s payout ratio is presently 82.49%.

Key Headlines Impacting Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Zacks also highlighted Colgate’s innovation strategy as a support for market share gains, with premium launches, pricing actions and science-based products helping growth in oral care and pet nutrition. Why Colgate’s Innovation Strategy Is Fueling Market Share Gains
• Neutral Sentiment: Analysts lowered near-term and longer-term EPS estimates, but the changes were relatively modest and the new forecasts still point to continued earnings growth over the next few years.
• Negative Sentiment: Zacks Research cut FY2026 EPS to $3.80 from $3.89, FY2027 to $4.01 from $4.15, FY2028 to $4.39 from $4.44, and reduced several quarterly estimates, signaling a slightly less optimistic profit outlook for Colgate-Palmolive. Analyst estimate cuts for Colgate-Palmolive

Analysts Set New Price Targets

CL has been the topic of several recent research reports. JPMorgan Chase & Co. boosted their price objective on shares of Colgate-Palmolive from $95.00 to $96.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Citigroup boosted their price objective on shares of Colgate-Palmolive from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $99.00 price target on shares of Colgate-Palmolive in a research note on Monday, May 4th. Morgan Stanley reaffirmed an “overweight” rating on shares of Colgate-Palmolive in a research note on Monday, May 4th. Finally, Wells Fargo & Company lowered their price target on shares of Colgate-Palmolive from $100.00 to $92.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Twelve analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $95.88.

Colgate-Palmolive Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.